NAS:CLRB (USA)
Business Description
Cellectar Biosciences Inc
NAICS : 325412
SIC : 2834
100 Campus Drive, Florham Park, NJ, USA, 07932
Compare
Compare
Traded in other countries / regions
NV4.Germany
•
CLRB.USA
Description
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and better safety as a result of fewer off-target effects. Its lead PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 113.46 | |||||
| Equity-to-Asset | 0.85 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 0 | |||||
| Beneish M-Score | -3.29 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 52 | |||||
| 3-Year EPS without NRI Growth Rate | 56.5 | |||||
| 3-Year FCF Growth Rate | 53.2 | |||||
| 3-Year Book Growth Rate | -38.9 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 72.8 | |||||
| 9-Day RSI | 62.42 | |||||
| 14-Day RSI | 58.75 | |||||
| 6-1 Month Momentum % | -26.34 | |||||
| 12-1 Month Momentum % | -58.81 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.75 | |||||
| Quick Ratio | 6.75 | |||||
| Cash Ratio | 6.59 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -134.6 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -62.06 | |||||
| ROA % | -55.87 | |||||
| ROIC % | -2831.16 | |||||
| ROC (Joel Greenblatt) % | -4501.51 | |||||
| ROCE % | -61.76 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.22 | |||||
| Price-to-Tangible-Book | 1.22 | |||||
| EV-to-EBIT | -0.11 | |||||
| EV-to-EBITDA | -0.11 | |||||
| EV-to-FCF | -0.12 | |||||
| Price-to-Net-Current-Asset-Value | 1.26 | |||||
| Price-to-Net-Cash | 1.23 | |||||
| Earnings Yield (Greenblatt) % | -909.09 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:CLRB
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0 | ||
| EPS (TTM) ($) | -4 | ||
| Beta | 1.58 | ||
| Volatility % | 52.61 | ||
| 14-Day RSI | 58.75 | ||
| 14-Day ATR ($) | 0.523966 | ||
| 20-Day SMA ($) | 4.590675 | ||
| 12-1 Month Momentum % | -58.81 | ||
| 52-Week Range ($) | 3.37 - 10.9 | ||
| Shares Outstanding (Mil) | 6.11 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cellectar Biosciences Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||